The regulators' decade: antitrust, disclosure and drug prices in the US

For a few years in the middle of the 2020s, a handful of American regulators tried to use the rulemaking power of the federal agencies to push economic policy in a more interventionist direction, and then ran into the courts. Between 2022 and 2024 the Federal Trade Commission, the Securities and Exchange Commission, and the antitrust enforcers at the Justice Department reached for tools that had sat largely idle for a generation. Factrail tracks the resulting actions not as a partisan score but as a study in the gap between announced intent and realized effect, because that gap is precisely where an accountability model earns its keep.

The interventionist turn

FTC Chair Lina Khan finalized a nationwide ban on most worker noncompete agreements in April 2024, a rule that would have freed millions of employees to change jobs without legal restraint. Six months earlier, in December 2023, the FTC and the Justice Department jointly issued tougher merger guidelines, signalling that regulators would scrutinise deals more sceptically than the permissive consensus of recent decades had allowed. At the SEC, Chair Gary Gensler adopted climate-risk disclosure rules in March 2024, requiring public companies to report certain climate-related risks to investors.

Factrail links these actions to the cost-of-living-pressure driver wherever a plausible wage or price effect exists. The logic is worth making explicit as analysis. A noncompete ban is, at bottom, a labour-market intervention: workers who can quit for a better offer tend to command higher wages, so banning the clauses that lock them in place is a plausible upward force on pay. Tougher merger review is a price story: fewer anticompetitive mergers means less concentrated market power and, in theory, less ability to mark up prices. Disclosure rules are subtler, shifting information toward investors rather than moving a price directly. The model attaches these links where the mechanism is credible, not everywhere a regulator happened to act.

The statute behind the agencies

None of this happened in a vacuum. The Inflation Reduction Act, negotiated chiefly by Senator Joe Manchin and Majority Leader Chuck Schumer and signed in August 2022, sits behind much of the period's economic activism. Among its provisions was authority for Medicare to negotiate the prices of certain high-cost drugs - a power the programme had been forbidden to use since its prescription-drug benefit was created. That authority produced the first ten negotiated Medicare prices in August 2024, which the Centers for Medicare and Medicaid Services estimated would cut beneficiaries' out-of-pocket costs by around 1.5 billion dollars when the prices take effect in 2026.

The drug-pricing measure is a useful contrast to the agency rules, because it rests on a different kind of authority. It was written into a statute passed by Congress and signed into law, not announced by a commission under a general grant of power. As analysis, that distinction matters for durability: a negotiated price grounded in explicit legislation is harder to dislodge than a rule an agency issues under contested interpretive authority. The model records the projected savings as an estimate, not a banked result, precisely because the prices were scheduled to bite in 2026 rather than already in effect.

What did not survive contact with the courts

The interventionist turn met sustained resistance, and not all of it stuck. The noncompete ban was struck down by a federal court before it ever took effect, leaving the millions of affected workers exactly where they had been. The SEC, for its part, later stopped defending its climate-disclosure rule, effectively abandoning the requirement rather than fighting for it through the courts. Factrail marks both of these facts for review, because their legal durability and their real-world impact are genuinely unsettled.

An official action's announced intent and its realized welfare effect can diverge sharply, which is why each fact carries its own sourcing and status.

That flag is not editorial hedging; it is the methodological point. A rule that is published, celebrated, and then vacated by a court has an announced intent but close to zero realized effect on the people it was meant to help. Scoring it as if the announcement equalled the outcome would systematically overstate what regulators accomplished. By keeping the status field honest - finalized, struck down, no longer defended - the model refuses to let a press release stand in for a result.

The through-line

The pattern across these events is ambition meeting friction. The merger guidelines and the Medicare drug-pricing authority have largely endured; the noncompete ban and the climate-disclosure rule have not. It is tempting to read that split ideologically, but a more careful reading is institutional. The measures with the firmer legal footing - a statute in the drug-pricing case, a more conventional exercise of established antitrust doctrine in the merger case - survived. The more aggressive assertions of agency authority, reaching further than courts were willing to follow, did not.

For an accountability model, the lesson generalises well beyond this particular cast of regulators. The welfare effect a citizen actually experiences depends not on what an official set out to do but on what survived the legal and political process that followed. A rule announced with fanfare and a rule still in force a year later deserve very different weight, and a dataset that conflated them would mislead its users about who delivered and who merely declared. Tracking the announced intent, the legal status, and the realized effect as three separate things is the discipline that keeps the record useful, and it is why this stretch of American economic regulation is logged as a story of partial, contested, and in several cases reversed achievement rather than a clean line of progress.